Fresenius Kabi issues separate recalls for drugs made at Illinois plant

A Fresenius Kabi worker
A Fresenius Kabi worker

German generics unit Fresenius Kabi issued two separate voluntary recalls for injectables produced at its plant in Illinois.

A Class II recall was put out by the company and posted on the FDA’s enforcement page for more than 96,000 units of the muscle relaxant cisatracurium besylate that are administered intravenously. The firm found the product had an incorrect statement of “preservative free” on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.

A Class III recall was issued for more than 48,000 units of the antipsychotic injectable drug haloperidol decanoate in 50 milligram doses due to an impurity out-of-specification result.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Both drugs are prescription-only products.

Back in 2012 and 2013, the generics maker had a spate of FDA warning letters for plants in Grand Island, NY, Kalyani, India, and Puerto Rico. It upgraded its plant in New York.

- access the FDA posting here

Read more on

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.